Skip to content Skip to footer
Subscribe Now
Cytokinetics
News

Cytokinetics Reports P-III (MAPLE-HCM) Trial Data of Aficamten for Obstructive Hypertrophic Cardiomyopathy

Shots: Cytokinetics has reported P-III (MAPLE-HCM) trial data assessing aficamten vs SoC metoprolol in pts (n=175) with symptomatic obstructive hypertrophic cardiomyopathy (HCM); regulatory review is ongoing in the US FDA (PDUFA: Dec 26, 2025) & EMA, with its NDA also under NMPA's priority review  The trial met its 1EP, showing superior improvement in peak oxygen…
May 14, 2025

Read more

Biopharma Deal Terminations Top 20 2021
TOP 20

Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

Shots: The biopharma industry saw numerous deal terminations in 2021. Clinical and regulatory results, change of control limitations, and strategic reprioritizations were among the most common reasons for deal termination. SOBI and Advent's acquisition agreement in 2021 ranked first under which Advent International offered to acquire SOBI. The second position goes to Galapagos’ development and…
March 10, 2022

Read more

Biopharma Deal Terminations Top 20 2020
TOP 20

Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. Sanofi and Hanmi's agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology- lapscovery. The second position goes to the…
February 11, 2021

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]